amitriptyline / Generic mfg. - LARVOL DELTA

Eye Pain in Dejerine-Roussy Syndrome: A Rare Post-Thalamic Stroke Manifestation - A Case Report. (PubMed, Case Rep Ophthalmol) - "The patient's neuropathic pain is being treated with gabapentin, amitriptyline, trazodone, and ibuprofen. The location of this patients' stroke, and his unique presentation, highlight a rare ocular manifestation clinicians should be aware of for their stroke patients' and their post-stroke management. Further, the unique resolution of this pain prompts more exploration into neuropathic pain treatment."

Journal • Cardiovascular • Cataract • Cerebral Hemorrhage • Hematological Disorders • Movement Disorders • Musculoskeletal Pain • Neuralgia • Ophthalmology • Pain

A Disorder of the Gut-Brain Interaction Presenting as "Thoracic Migraine" (ACG 2026) - "In addition to ongoing migraine management, he was started on Amitriptyline (uptitrated to 25 mg QD) and referred to psychiatry alongside continued gastroenterology follow-up...Figure: Figure 2: High resolution manometry images at supine (image 2A) and upright (image 2B). Provocation testing performed with multiple rapid swallows (image 2C)."

CNS Disorders • Constipation • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology • Migraine

African American Patients With Cyclic Vomiting Syndrome Have Higher Healthcare Utilization and Lower Guideline-Directed Therapy: A Propensity-Score-Matched Analysis of the TriNetX US Collaborative Network (ACG 2026) - "Outcomes assessed over 365 days included ambulatory visits, ED visits, inpatient admissions (IP), CT abdomen utilization, esophagogastroduodenoscopy (EGD), colonoscopy and CVS-directed medications (amitriptyline, nortriptyline, topiramate, aprepitant). After 1:1 PSM, 7,504 matched pairs were analyzed. African American patients had lower ambulatory care utilization (76.6% vs 81.5%; RR 0.941) but higher ED visits (41.2% vs 31.0%; RR 1.327), IP admissions (23.7% vs 18.4%; RR 1.286), and CT utilization (15.3% vs 12.3%; RR 1.239). EGD and colonoscopy utilization were similar."

Clinical • HEOR • CNS Disorders • Gastrointestinal Disorder • Rare Diseases

Graph-Theoretic Symptom Network Model for Irritable Bowel Syndrome: A Data-Driven Precision Medicine Framework (ACG 2026) - "We calibrated treatment response projections using TARGET-3 rifaximin retreatment data (n=636; abdominal pain responder rate 53.9% vs 44.4% placebo, p=0.02; composite endpoint 35.4% vs 25.6% LOCF), ATLANTIS amitriptyline trial (n=463; IBS-SSS difference â27.0 points, 95% CI â46.9 to â7.1, p=0.0079; global relief OR=1.78), and low-FODMAP RCTs (Staudacher 2011: overall control 68% vs 23% at 4 weeks, bloating 74% vs 32%, urgency 53% vs 23%; Goyal 2021: responder rate 62.7% vs 40.8%, p=0.0448; meta-analysis SMD â0.66, IBS-SSS reduction ~45 points). Network analysis identified Bloating as the top hub (degree strength 4.03), followed by Dissatisfaction (3.80), Urgency (3.77), Pain (3.61), and Diarrhea (3.57). Lethargy emerged as the primary bridge symptom (betweenness centrality 0.476). Community detection revealed two clusters: Community 1 (Pain, Bloating, Urgency, Diarrhea, Dissatisfaction; modularity Q=0.019) and Community 2 (Constipation, Nausea,..."

Constipation • Gastroenterology • Gastrointestinal Disorder

Ketamine-Assisted Psychotherapy as a Novel Treatment for Refractory Irritable Bowel Syndrome: A Case Series (ACG 2026) - "He had previously failed treatment with as-needed loperamide, psyllium fiber, amitriptyline, alprazolam, and cognitive behavioral therapy...She had previously attempted a low-FODMAP and gluten-free diet, and had failed trials of an antispasmodic, psyllium fiber, and desipramine...By modulating central sensitization and the gut-brain axis, KAP may address both the visceral hypersensitivity and psychological comorbidities inherent to IBS. This case series represents the first report highlighting KAP as a potential therapy for refractory IBS, while more trials are currently underway."

Clinical • Cardiovascular • CNS Disorders • Depression • Diabetes • Gastrointestinal Disorder • Hypertension • Immunology • Metabolic Disorders • Mood Disorders • Post-traumatic Stress Disorder • Type 2 Diabetes Mellitus

SMPD1 Inhibition Attenuates Abdominal Aortic Aneurysm via Ceramide-Mediated NLRP3 Inflammatory Pathway. (PubMed, Arterioscler Thromb Vasc Biol) - "Pharmacological inhibition of SMPD1 with amitriptyline attenuated AAA progression. Integrated Mendelian randomization and experimental evidence identified SMPD1 as a novel AAA driver through the ceramide (d18:1/16:0)-mediated NLRP3 pathway, establishing SMPD1 as a promising therapeutic target."

Journal • Cardiovascular • Inflammation • ELANE • IL6R • MMP1 • NLRP3

QTc changes and early major adverse cardiovascular events associated with antidepressant treatment for major depressive disorder in adults: individual participant data network meta-regression of double blind randomised trials. (PubMed, BMJ) - "The effect of specific antidepressants on QTc interval differed between adults with depression. No evidence associated antidepressant use with early MACE and non-suicidal sudden death. To support shared decision making and taking into account the trade-off between benefits and harms, individual modifiable and non-modifiable risk factors should be considered when choosing antidepressants."

Adverse events • Clinical • Journal • Cardiovascular • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Healthcare providers' perspectives on headache care in Azerbaijan: results of a national cross-sectional survey. (PubMed, Front Neurol) - "The most commonly reported preventive medications were amitriptyline (75.7%), magnesium (51.1%), gabapentin (24.6%), and valproate (24.3%). Because the survey was based on healthcare providers' perceptions derived from a convenience sample, the findings should be interpreted as complementary to, rather than substitutes for, patient-level or administrative health-system data. Future nationally representative studies are needed to guide the development of structured, evidence-based headache services."

Journal • CNS Disorders • Migraine • Pain • Pediatrics

Amitriptyline as a potential new therapy for asthma: anti-obstructive, immunomodulatory, or both? (ERS 2026) - "These findings indicate that inhaled amitriptyline seems to be a new and highly effective anti-obstructive therapy in allergic asthma, mainly through direct effects on airway smooth muscle rather than systemic immune modulation."

Immunomodulating • Asthma • Immune Modulation • Immunology • Inflammation • Respiratory Diseases

Drugs for prevention of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Comparison table: Some drugs for migraine prevention. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Comparative Effectiveness of Pregabalin With Duloxetine Versus Pregabalin With Amitriptyline in Chronic Low Back Pain With Radiculopathy: A Prospective Comparative Study. (PubMed, Health Sci Rep) - "In this non-randomized cohort, the pregabalin-duloxetine combination was associated with greater crude improvement, and duloxetine-treated participants reported fewer episodes of sedation and drowsiness; however, the apparent efficacy advantage was substantially attenuated after accounting for baseline imbalance, and because adverse-event ascertainment was open-label and incomplete, the tolerability signal also remains exploratory. These findings should be regarded as hypothesis-generating and require confirmation in adequately powered randomized trials."

HEOR • Journal • Anesthesia • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

Chronic Migraine Remission with Combination of Remote Electrical Neuromodulation (REN) and In-Clinic / Patient-Administered Sphenopalatine Ganglion (SPG) Block (PAINWeek 2026) - "Current acute treatments included rizatriptan, ubrogepant and acetaminophen with recent discontinued acute therapies including rimegepant and NSAIDS. Current preventative treatments include onabotulinumtoxinA, galcanezumab, amitriptyline, cyclobenzaprine, ondansetron and occipital nerve blocks with recent discontinued preventatives including topiramate... Patient was seen weekly for initial treatment sequence and noted near complete resolution of acute migraine symptoms after the first in-clinic SPG administration with smaller, although noticeable, levels of relief with self-administered SPG administration. Patient also noted significant, although not complete, reduction of acute pain and nausea within the first week of initiating REN. After one month of treatment, patient noted that migraine frequency reduced to one episode per week from the previous 4 to 6 episodes and was able to manage most acute episodes with acetaminophen, with rare need for other acute..."

Clinical • CNS Disorders • Depression • Migraine

Comparative efficacy of antidepressants for acute adolescent major depressive disorder: a source-verified systematic review and network meta-analysis. (PubMed, Front Psychiatry) - "The antidepressant-only primary SMD network contained 4 parent trials and 11 randomized arms, including desipramine, amitriptyline, fluoxetine, levomilnacipran 40 mg, levomilnacipran 80 mg, vilazodone 15 mg, vilazodone 30 mg, and pill placebo. The only statistically significant estimate was derived from a small historical desipramine trial with important data-quality limitations. Adolescent-specific arm-level evidence was too sparse and methodologically limited to support a stable comparative efficacy hierarchy among antidepressants."

Journal • Retrospective data • Review • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society. (PubMed, Headache) - "This SR provides a comprehensive synthesis of evidence on pharmacologic migraine prevention in adults. High- and moderate-confidence findings confirm the efficacy of several established and newer preventive therapies and demonstrate improvements in patient-reported outcomes across multiple validated measures. These conclusions informed the development of evidence-based recommendations, presented in a companion publication, to guide clinicians in selecting preventive medications for adults with episodic and chronic migraine."

Journal • CNS Disorders • Migraine • Pain

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society. (PubMed, Neurology) - "This SR provides a comprehensive synthesis of evidence on pharmacologic migraine prevention in adults. High- and moderate-confidence findings confirm the efficacy of several established and newer preventive therapies and demonstrate improvements in patient-reported outcomes across multiple validated measures. These conclusions informed the development of evidence-based recommendations, presented in a companion publication, to guide clinicians in selecting preventive medications for adults with episodic and chronic migraine."

Journal • Review • CNS Disorders • Migraine • Pain

Exploring a Persistent Terbinafine - CYP2D6 Interaction Using Physiologically - Based Pharmacokinetic Modeling. (PubMed, AAPS J) - "Experimentally determined Kiu,CYP2D6 for TBNF and DMT enabled to predict the interaction with CYP2D6 substrates Desipramine, Amitriptyline and Nortriptyline. This PBPK framework can be applied in different clinical pharmacology settings for drugs characterized by extensive distribution, formation rate limited metabolism and enzyme inhibition. The framework provides applicability in informing the rational design of clinical trials where sustained plasma drug levels warrant patient monitoring long after termination of dosing."

Journal • PK/PD data • Infectious Disease

Treating Intractable Nausea and Vomiting in Cerebellar and Medullary Stroke. (PubMed, Cureus) - "Ondansetron and metoclopramide provided only limited or temporary relief. Symptoms improved after sequential escalation to ondansetron, chlorpromazine, prochlorperazine, and amitriptyline; transdermal scopolamine was included in the discharge regimen...Because multiple medications were introduced over a short interval and natural neurologic recovery may have contributed, the effect of any individual agent or combination cannot be determined. This case suggests that receptor-diverse pharmacotherapy may be considered when initial treatment fails while underscoring the need for further study of efficacy, safety, and medication sequencing."

Journal • Cardiovascular • Diabetes • Gastrointestinal Disorder • Metabolic Disorders

Responding With Evidence and Access for Childhood Headaches (REACH) study: A comparative effectiveness trial of cognitive behavioral therapy monotherapy versus combined cognitive behavioral therapy-pharmacotherapy with amitriptyline for the prevention of childhood migraine-The study protocol. (PubMed, Headache) - "This trial is designed to reinforce current guidelines for preventive headache management strategies in youth with migraine. The study will also advance knowledge by determining whether CBT alone, without the potential side effects of medication, is sufficient."

HEOR • Journal • Monotherapy • CNS Disorders • Migraine • Pain • Pediatrics

Treatment outcomes in primary nummular headache: a systematic review. (PubMed, Front Pharmacol) - "Evidence for amitriptyline, lamotrigine, pregabalin, and other therapies was limited to smaller samples and showed variable efficacy...Current evidence suggests that onabotulinumtoxinA offers the most favorable efficacy-tolerability profile, while gabapentin is effective but limited by tolerability concerns...Prospective comparative studies with standardized outcome measures are urgently needed to establish definitive treatment guidelines for this disabling headache disorder. Identifier CRD420261375695."

Journal • Review • CNS Disorders • Migraine • Pain

Discontinuing Psychotropic Medication Before Psychotherapy for PTSD (clinicaltrials.gov) - P=N/A | N=100 | Not yet recruiting | Sponsor: Academic Centre for Dentistry in Amsterdam

New trial • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Inhibition of sodium-calcium exchanger by tricyclic antidepressants. (PubMed, Front Pharmacol) - "Tricyclic antidepressants (TCAs) such as amitriptyline, desipramine, and clomipramine are widely used for the treatment of neuropathic pain, yet the cellular mechanisms underlying their analgesic effects remain incompletely understood. These results provide direct evidence that amitriptyline inhibits NCX activity and alters neuronal Ca2+ handling. This effect may contribute to enhanced Ca2+-dependent desensitization of NMDA receptors and suppression of excitatory signaling, providing a mechanistic explanation of its analgetic properties."

Journal • Neuralgia • Pain

COPE Trial: comparison of yoga therapy versus medical therapy in men with chronic pelvic pain syndrome-a pilot randomised crossover trial. (PubMed, Int Urol Nephrol) - "YT was not inferior to alfuzosin plus amitriptyline (MT) for improving symptoms in men with CPPS and had fewer side effects. Yoga could be used as an add-on or maintenance therapy while MT could be more preferable in men with predominant urinary symptoms."

Journal • Gynecology • Musculoskeletal Pain • Pain • Urology

Association between antidepressant use and the risk of type 2 diabetes: a multi-stage Mendelian randomization study. (PubMed, Eur Arch Psychiatry Clin Neurosci) - "This study provides genetic evidence suggesting medication-specific associations between antidepressant use liability and T2D susceptibility. Although the observed effect sizes were modest, these results highlight that the metabolic effects of individual antidepressants may vary, thus, warranting further studies to determine the clinical relevance of our findings."

Journal • CNS Disorders • Depression • Diabetes • Metabolic Disorders • Psychiatry • Type 2 Diabetes Mellitus

LATENT CLASS ANALYSIS PREDICTS PATIENTS WITH IRRITABLE BOWEL SYNDROME WHO RESPOND TO AMITRIPTYLINE: POST HOC ANALYSES FROM THE ATLANTIS TRIAL (UEGW 2026) - No abstract available

Clinical • Retrospective data • Gastrointestinal Disorder